A Clinical Trial To Evaluate the Toxicity and Antiviral Effects of a Range of Doses of Ampligen in p24 Antigen Positive HIV-Infected Patients With AIDS or ARC
This study has been completed.
Study NCT00000735
Information provided by National Institute of Allergy and Infectious Diseases (NIAID)
First Received on November 2, 1999.
Last Updated on March 30, 2012
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
